Literature DB >> 17868274

Orthotopic liver transplantation for subacute hepatic failure following partial treatment of isoniazid-resistant tuberculosis.

K L Nash1, T M Yeung, P J Lehner, P Gibbs, W J H Griffiths.   

Abstract

The management of patients with pre-existing tuberculosis (TB) undergoing liver transplantation is challenging. Cautious immunosuppression is required to prevent reactivation of disease, and second-line anti-tuberculous treatment may be necessary to prevent graft hepatotoxicity. Furthermore, liver transplantation in the context of isoniazid-resistant TB has seldom been reported. We report on a 44-year-old man with recent isoniazid-resistant extra-pulmonary TB who developed subacute hepatic failure requiring emergency liver transplantation and treatment with second-line anti-tuberculous therapy. We demonstrate that patients who have pre-existing TB can be successfully treated with alternative anti-tuberculous medication while under immunosuppression post transplantation. Pre-existing TB, including resistant strains, should not be an absolute contraindication to liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868274     DOI: 10.1111/j.1399-3062.2007.00277.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  2 in total

1.  Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system.

Authors:  David S Goldberg; Kimberly A Forde; Dena M Carbonari; James D Lewis; Kimberly B F Leidl; K Rajender Reddy; Kevin Haynes; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley; Vincent Lo Re
Journal:  Gastroenterology       Date:  2015-02-28       Impact factor: 22.682

2.  Liver Transplantation in Antituberculosis Drugs-Induced Fulminant Hepatic Failure: A Case Report and Review of the Literature.

Authors:  Xiaoyan Li; Yujie Liu; Erhong Zhang; Qiong He; Yong-Bo Tang
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.